All News
Bridging the gap in the delayed diagnosis of axSpA
Delay in the diagnosis of axial spondyloarthritis (axSpA) has been a huge challenge and is associated with poor outcomes.
Read Article
⭐️C-OPTIMISE:
Early, active AxSpA on certilozumab (CZP) 200mg q2w x 48w. Then, if remission, randomized to CZP q2w vs q4w vs PBO x 48w
➡️No flare in PBO BUT w/ ↑:
*️⃣ASDAS + BASDAI
*️⃣CRP + fecal calprotectin
Thus, keep some dose of CZP on!
Abst#0916 #ACR21 @RheumNow https://t.co/DT8FKHAhr0
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️Imaging of the SIJ in psoriatic axSpA is similar to axSpA associated with iritis or colitis!
Abst#0902 (https://t.co/f55Vfi1LSS)
#ACR21 @RheumNow https://t.co/UCXrwPiyhh
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression.
#Abs0909 #ACR21 @RheumNow
https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh
Mrinalini Dey DrMiniDey ( View Tweet)
Predictors of clinical remission in AS patients Rx with TNFi
⭐️Age and 3-mo BASDAI improvement➡️ predictor of clinical remission criteria
⭐️Normalized ESR and CRP at month 3 were predictors of achievement of BASDAI-CRP
Abst#0931 #ACR21 @RheumNow https://t.co/Ot1ypgNg3A
swethaann23 swethaann23 ( View Tweet)
Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission:
⭐️🔼Baseline physician global VAS 🔼flare in 16 weeks after tapering to 2/3 of standard dose.
⭐️🔼Age 🔼flare within 16 weeks after tapering to 1/2 dose
Abst #0929 #ACR21 @RheumNow https://t.co/EFiwKA8z99
swethaann23 swethaann23 ( View Tweet)
AxSpA pts who achieve ASDAS low disease activity (LDA) 6 mo after bDMARD initiation
⭐️ 25% achieved ASDAS LDA
⭐️ASDAS LDA achievers were ♂️ + naïve to c/b DMARDs + with PROM / Clinical improvement
⭐️ASDAS LDA non-achievers=depression, uveitis, IBD
Abst# 0925 #ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
Turkish study finds that ETN may be negatively associated w/ the development of ADA in AS pts. Abs 0936 #ACR21 #RheumNow @RheumNow https://t.co/z3pYDpp1NN https://t.co/MR1R41rCHV
Dr. Rachel Tate uptoTate ( View Tweet)
Evaluate effectiveness and Rx survival of different TNFI in cohort of axSpA
⭐️No difference among different TNFI
⭐️No difference between nr-axSpA and AS
⭐️Failure to initial TNFI did not diminish effectiveness or drug survival of subsequent TNFi Rx
Abst#0938 #ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
Abst0897 #ACR21 @RheumNow radiographic progression in AS accelerates w/age, highest at age 30–39 (mean mSASSS change per year 1.148), followed by 40–49 , 20–29,≥50 & least < 20 (0.643). radiographic damage rapidly ⬆️ among 20s w/risk factors:⬆️ CRP &preexisting syndesmophytes https://t.co/tiAgKUyjJq
Olga Petryna DrPetryna ( View Tweet)
SELECT-AXIS 1: UPA 15 mg QD consistently efficacious over 2 years for ASAS40. Low radiographic progression rates in AS pts. No new safety findings were observed. Abs 0924 #ACR21 #RheumNow @RheumNow https://t.co/CWvH1OPGyR https://t.co/uC67fJZDCE
Dr. Rachel Tate uptoTate ( View Tweet)
SELECT-AXIS 1 Post Hoc Analysis results showed improvement in PROs & reduction in back pain score at 12 weeks predicted clinical outcomes at 1 year in AS pts. Abs 0926 #ACR21 #RheumNow @RheumNow https://t.co/vRVpv1O6YS https://t.co/wjafMf1UPY
Dr. Rachel Tate uptoTate ( View Tweet)
SEC reduced SIJ bone marrow edema in active nr-axSpA pts. Majority of pts both in SEC and PBO arms showed no radiographic progression through 2 years. Abs 0921 #ACR21 #RheumNow @RheumNow https://t.co/yC2AZoacxF https://t.co/pjCL8HCanR
Dr. Rachel Tate uptoTate ( View Tweet)
Googling rheumatic diseases. On average google search lacked essential information to guide patient decisions. Websites on AS scored the highest on the DISCERN and RA scored the highest on JAMA @RheumNow #ACR21 Abst#0742 https://t.co/k2o2AqYEeh https://t.co/ZKljvA2f4O
Dr. Antoni Chan synovialjoints ( View Tweet)
Factors associated with Anti Drug Ab against TNFi over 2-y in axSpA pts are:
⭐️ 🔼 Disease activity
⭐️Development of adverse events
⭐️Treatment discontinuation
Abst #0936 #ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
Physician global score was the strongest predictor of future flares in AS patients with TNFi dose tapering. 29 (27%) flared at 2/3 of standard
dose, 21 (20%) at 1/2 dose, 29 (27%) at 1/3 dose and 27 (25%) after discontinuation @RheumNow #ACR21 Abst#0929 https://t.co/pIzLgexe3k https://t.co/UM9cGLiYl7
Dr. Antoni Chan synovialjoints ( View Tweet)
SKIPPAIN results: Spinal pain response after 8 weeks of SEC showed notable differences between HLA-B27 subgroups. Can subtype pre-determine tx efficacy/response? Abs 0917 #ACR21 #RheumNow @RheumNow https://t.co/FKpCqXpobM https://t.co/WbjjyTIaiG
Dr. Rachel Tate uptoTate ( View Tweet)
GO-ALIVE study by Prof ADeodhar & grp
🔘IV GOL was shown to be effective across all efficacy outcomes in AS pts w/ early & late dse
🔘⬆proportions of pts w/ early dse achieved BASDAI50 and ASDAS inactive dse
Early dx and tx 👉better outcomes
@RheumNow #ACR21 #ACRBest abs0912 https://t.co/jwvEn5LdDB
sheila RHEUMarampa ( View Tweet)
Physician global score only predictor of axSpA flares when tapering TNFi
⭐️Changes in imaging did not predict flare
Abs#929
#ACR21 @RheumNow
https://t.co/vVn6ARKJu0 https://t.co/FlVtlLmTfl
Robert B Chao, MD doctorRBC ( View Tweet)
French real-world AxSpA cohort analysis showed drug retention of SEC & TNFi were similar. In subgroups analyses, age, BASDAI at dx & BMI were similar. Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/ewtmpxKTNu https://t.co/Yh0nX3x83Z
Dr. Rachel Tate uptoTate ( View Tweet)
